Please login to the form below
colorectal cancer
This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq combo scores FDA approval for melanoma
When receiving a cancer immunotherapy combined with targeted therapies, patients with BRAF V600 mutation-positive advanced melanoma were able to live for more than 15 months without their disease worsening," said ... mark in advanced colorectal cancer.
Latest news
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
Gilead Sciences has bulked up its oncology pipeline with a $4.9 billion all-cash deal to acquire Forth Seven, which specialises in cancer immunotherapies targeting the CD47 immune checkpoint. ... Forty Seven is also testing the drug in patients with
-
Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC
voting in favour of its use in first-line, metastatic non-small cell lung cancer. ... Cyramza – a VEGF receptor 2 agonist – is already approved in a number of additional indications, including oesophageal cancer, gastric cancer, NSCLC after
-
Eisai agrees to pull obesity drug Belviq after safety alert
Weight-loss drug linked to increased risk of cancer. Eisai has moved swiftly to comply with an FDA request to pull its obesity drug Belviq off the market after it was ... In 2010, the FDA rejected the first marketing application for the drug, filed by
-
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
The aim was to use the platform to discover new cancer targets, and develop and commercialise the resulting therapies. ... The trial included patients with non-small cell lung cancer, ovarian cancer, melanoma, breast cancer and colorectal cancer and all
-
Nektar’s opioid analgesic slammed with FDA panel rejection
across a number of cancer types. ... This includes studies, either underway or planned, in small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer, sarcoma, melanoma, renal cell carcinoma, bladder cancer
More from news
Approximately 16 fully matching, plus 220 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... If successful, that would dramatically increase the eligible patient population in breast cancer as well as
-
Pharma deals continue to slide
CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.
-
Winning the war against cancer
data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.
-
Deal Watch September 2016
Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to
More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
Kite Pharma appoints head of regulatory affairs
colorectal cancer. ... Other recent additions include chief financial officeras chief medical officer; and several cancer experts to the company's scientific advisory board.
-
Boston Biomedical appoints commercial head
colorectal cancer.
-
Mirna hires former Pfizer director as CMO
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... This background will benefit Mirna, which has just
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Early diagnosis underpins NHS cancer strategy
In addition, Cancer Alliances will also implement a new timed diagnostic pathway for specific cancers, building on the timed pathways already being introduced in lung, colorectal and prostate cancer. ... suspected symptoms to RDCs, supported by the local
-
Artificial Intelligence in healthcare
trust the same digital system to recommend their treatment pathway for a potentially lethal cancer. ... Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
-
Lynch syndrome: a patient perspective
My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... colon cancer as a cause of death in families where half their members previously died for the disease.
-
90TEN nominated for five Communiqué Awards
Meanwhile two of the agency’s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
